Overall prognostic impact of C-reactive protein level in patients with metastatic renal cell carcinoma treated with sorafenib
C-reactive protein (CRP) is an independent prognostic factor for renal cell carcinoma (RCC). The aim of the present study was to investigate the overall prognostic impact of CRP in patients with metastatic RCC treated with sorafenib. Between April 2008 and December 2014, 40 consecutive patients with...
Gespeichert in:
| Veröffentlicht in: | Anti-cancer drugs 2016-11, Vol.27 (10), p.1028-1032 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1032 |
|---|---|
| container_issue | 10 |
| container_start_page | 1028 |
| container_title | Anti-cancer drugs |
| container_volume | 27 |
| creator | Fujita, Tetsuo Nishi, Morihiro Tabata, Ken-ichi Matsumoto, Kazumasa Yoshida, Kazunari Iwamura, Masatsugu |
| description | C-reactive protein (CRP) is an independent prognostic factor for renal cell carcinoma (RCC). The aim of the present study was to investigate the overall prognostic impact of CRP in patients with metastatic RCC treated with sorafenib. Between April 2008 and December 2014, 40 consecutive patients with metastatic RCC were treated with sorafenib at our institution. The patients were divided into two cohorts according to the pretreatment CRP level(i) a normal CRP cohort (≤0.30 mg/dl) and (ii) an elevated CRP cohort (>0.30 mg/dl). Kaplan–Meier overall survival analysis was carried out. The effects of selected variables on survival were assessed by multivariate regression using the Cox proportional hazards model. The normal CRP cohort included 16 patients (40.0%) and the elevated CRP cohort included 24 patients (60.0%). The normal CRP cohort showed significantly longer overall survival than the elevated CRP cohort (median, 52.0 vs. 17.0 months; P=0.0072). On multivariate analysis, normal CRP predicted longer overall survival (hazard ratio, 0.367; 95% confidence interval, 0.147−0.914; P=0.0313). Pretreatment normal CRP predicted better overall survival in patients with metastatic RCC treated with sorafenib and CRP level may be a useful biomarker for predicting overall survival of patients treated with sorafenib. |
| doi_str_mv | 10.1097/CAD.0000000000000417 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1855072927</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1823034162</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3897-f145bccf60b12ef24338cb054529d1eadb28f22c8f6dcb0ec724277e064955af3</originalsourceid><addsrcrecordid>eNqNkUtLAzEUhYMoWh__QCRLN1PzbGaWUp8guNH1kMnc2GhmpiZpiwv_uylVERdiNrnc-52TXA5Cx5SMKanU2fT8Ykx-HkHVFhpRoXghlaDbaEQqWRWiUnwP7cf4nJnc57tojynJlSBkhN7vlxC093gehqd-iMkZ7Lq5NgkPFk-LALl0S1jPE7gee1iCx7mY6-SgTxGvXJrhDpKOSa_lAXrtsYFsanQwrh86jVM2StBu4DgEbaF3zSHasdpHOPq8D9Dj1eXD9Ka4u7--nZ7fFYaXlSosFbIxxk5IQxlYJjgvTUOkkKxqKei2YaVlzJR20uY-GMUEUwrIRFRSassP0OnGN2_xuoCY6s7F9Q91D8Mi1rSUkihWMfUPlHHCBZ2wjIoNasIQYwBbz4PrdHirKanXGdU5o_p3Rll28vnCoumg_RZ9hZKBcgOsBp8gxBe_WEGoZ6B9mv3t_QG_dZ8D</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1823034162</pqid></control><display><type>article</type><title>Overall prognostic impact of C-reactive protein level in patients with metastatic renal cell carcinoma treated with sorafenib</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Fujita, Tetsuo ; Nishi, Morihiro ; Tabata, Ken-ichi ; Matsumoto, Kazumasa ; Yoshida, Kazunari ; Iwamura, Masatsugu</creator><creatorcontrib>Fujita, Tetsuo ; Nishi, Morihiro ; Tabata, Ken-ichi ; Matsumoto, Kazumasa ; Yoshida, Kazunari ; Iwamura, Masatsugu</creatorcontrib><description>C-reactive protein (CRP) is an independent prognostic factor for renal cell carcinoma (RCC). The aim of the present study was to investigate the overall prognostic impact of CRP in patients with metastatic RCC treated with sorafenib. Between April 2008 and December 2014, 40 consecutive patients with metastatic RCC were treated with sorafenib at our institution. The patients were divided into two cohorts according to the pretreatment CRP level(i) a normal CRP cohort (≤0.30 mg/dl) and (ii) an elevated CRP cohort (>0.30 mg/dl). Kaplan–Meier overall survival analysis was carried out. The effects of selected variables on survival were assessed by multivariate regression using the Cox proportional hazards model. The normal CRP cohort included 16 patients (40.0%) and the elevated CRP cohort included 24 patients (60.0%). The normal CRP cohort showed significantly longer overall survival than the elevated CRP cohort (median, 52.0 vs. 17.0 months; P=0.0072). On multivariate analysis, normal CRP predicted longer overall survival (hazard ratio, 0.367; 95% confidence interval, 0.147−0.914; P=0.0313). Pretreatment normal CRP predicted better overall survival in patients with metastatic RCC treated with sorafenib and CRP level may be a useful biomarker for predicting overall survival of patients treated with sorafenib.</description><identifier>ISSN: 0959-4973</identifier><identifier>EISSN: 1473-5741</identifier><identifier>DOI: 10.1097/CAD.0000000000000417</identifier><identifier>PMID: 27537400</identifier><language>eng</language><publisher>England: Copyright Wolters Kluwer Health, Inc. All rights reserved</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents - therapeutic use ; Carcinoma, Renal Cell - blood ; Carcinoma, Renal Cell - drug therapy ; Carcinoma, Renal Cell - surgery ; Cohort Studies ; Female ; Humans ; Kidney Neoplasms - blood ; Kidney Neoplasms - drug therapy ; Kidney Neoplasms - surgery ; Male ; Middle Aged ; Niacinamide - analogs & derivatives ; Niacinamide - therapeutic use ; Phenylurea Compounds - therapeutic use ; Prognosis ; Proportional Hazards Models ; Protein Kinase Inhibitors - therapeutic use ; Retrospective Studies ; Survival Rate</subject><ispartof>Anti-cancer drugs, 2016-11, Vol.27 (10), p.1028-1032</ispartof><rights>Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3897-f145bccf60b12ef24338cb054529d1eadb28f22c8f6dcb0ec724277e064955af3</citedby><cites>FETCH-LOGICAL-c3897-f145bccf60b12ef24338cb054529d1eadb28f22c8f6dcb0ec724277e064955af3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27537400$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fujita, Tetsuo</creatorcontrib><creatorcontrib>Nishi, Morihiro</creatorcontrib><creatorcontrib>Tabata, Ken-ichi</creatorcontrib><creatorcontrib>Matsumoto, Kazumasa</creatorcontrib><creatorcontrib>Yoshida, Kazunari</creatorcontrib><creatorcontrib>Iwamura, Masatsugu</creatorcontrib><title>Overall prognostic impact of C-reactive protein level in patients with metastatic renal cell carcinoma treated with sorafenib</title><title>Anti-cancer drugs</title><addtitle>Anticancer Drugs</addtitle><description>C-reactive protein (CRP) is an independent prognostic factor for renal cell carcinoma (RCC). The aim of the present study was to investigate the overall prognostic impact of CRP in patients with metastatic RCC treated with sorafenib. Between April 2008 and December 2014, 40 consecutive patients with metastatic RCC were treated with sorafenib at our institution. The patients were divided into two cohorts according to the pretreatment CRP level(i) a normal CRP cohort (≤0.30 mg/dl) and (ii) an elevated CRP cohort (>0.30 mg/dl). Kaplan–Meier overall survival analysis was carried out. The effects of selected variables on survival were assessed by multivariate regression using the Cox proportional hazards model. The normal CRP cohort included 16 patients (40.0%) and the elevated CRP cohort included 24 patients (60.0%). The normal CRP cohort showed significantly longer overall survival than the elevated CRP cohort (median, 52.0 vs. 17.0 months; P=0.0072). On multivariate analysis, normal CRP predicted longer overall survival (hazard ratio, 0.367; 95% confidence interval, 0.147−0.914; P=0.0313). Pretreatment normal CRP predicted better overall survival in patients with metastatic RCC treated with sorafenib and CRP level may be a useful biomarker for predicting overall survival of patients treated with sorafenib.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Carcinoma, Renal Cell - blood</subject><subject>Carcinoma, Renal Cell - drug therapy</subject><subject>Carcinoma, Renal Cell - surgery</subject><subject>Cohort Studies</subject><subject>Female</subject><subject>Humans</subject><subject>Kidney Neoplasms - blood</subject><subject>Kidney Neoplasms - drug therapy</subject><subject>Kidney Neoplasms - surgery</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Niacinamide - analogs & derivatives</subject><subject>Niacinamide - therapeutic use</subject><subject>Phenylurea Compounds - therapeutic use</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><issn>0959-4973</issn><issn>1473-5741</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUtLAzEUhYMoWh__QCRLN1PzbGaWUp8guNH1kMnc2GhmpiZpiwv_uylVERdiNrnc-52TXA5Cx5SMKanU2fT8Ykx-HkHVFhpRoXghlaDbaEQqWRWiUnwP7cf4nJnc57tojynJlSBkhN7vlxC093gehqd-iMkZ7Lq5NgkPFk-LALl0S1jPE7gee1iCx7mY6-SgTxGvXJrhDpKOSa_lAXrtsYFsanQwrh86jVM2StBu4DgEbaF3zSHasdpHOPq8D9Dj1eXD9Ka4u7--nZ7fFYaXlSosFbIxxk5IQxlYJjgvTUOkkKxqKei2YaVlzJR20uY-GMUEUwrIRFRSassP0OnGN2_xuoCY6s7F9Q91D8Mi1rSUkihWMfUPlHHCBZ2wjIoNasIQYwBbz4PrdHirKanXGdU5o_p3Rll28vnCoumg_RZ9hZKBcgOsBp8gxBe_WEGoZ6B9mv3t_QG_dZ8D</recordid><startdate>201611</startdate><enddate>201611</enddate><creator>Fujita, Tetsuo</creator><creator>Nishi, Morihiro</creator><creator>Tabata, Ken-ichi</creator><creator>Matsumoto, Kazumasa</creator><creator>Yoshida, Kazunari</creator><creator>Iwamura, Masatsugu</creator><general>Copyright Wolters Kluwer Health, Inc. All rights reserved</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TO</scope><scope>H94</scope></search><sort><creationdate>201611</creationdate><title>Overall prognostic impact of C-reactive protein level in patients with metastatic renal cell carcinoma treated with sorafenib</title><author>Fujita, Tetsuo ; Nishi, Morihiro ; Tabata, Ken-ichi ; Matsumoto, Kazumasa ; Yoshida, Kazunari ; Iwamura, Masatsugu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3897-f145bccf60b12ef24338cb054529d1eadb28f22c8f6dcb0ec724277e064955af3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Carcinoma, Renal Cell - blood</topic><topic>Carcinoma, Renal Cell - drug therapy</topic><topic>Carcinoma, Renal Cell - surgery</topic><topic>Cohort Studies</topic><topic>Female</topic><topic>Humans</topic><topic>Kidney Neoplasms - blood</topic><topic>Kidney Neoplasms - drug therapy</topic><topic>Kidney Neoplasms - surgery</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Niacinamide - analogs & derivatives</topic><topic>Niacinamide - therapeutic use</topic><topic>Phenylurea Compounds - therapeutic use</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fujita, Tetsuo</creatorcontrib><creatorcontrib>Nishi, Morihiro</creatorcontrib><creatorcontrib>Tabata, Ken-ichi</creatorcontrib><creatorcontrib>Matsumoto, Kazumasa</creatorcontrib><creatorcontrib>Yoshida, Kazunari</creatorcontrib><creatorcontrib>Iwamura, Masatsugu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Anti-cancer drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fujita, Tetsuo</au><au>Nishi, Morihiro</au><au>Tabata, Ken-ichi</au><au>Matsumoto, Kazumasa</au><au>Yoshida, Kazunari</au><au>Iwamura, Masatsugu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Overall prognostic impact of C-reactive protein level in patients with metastatic renal cell carcinoma treated with sorafenib</atitle><jtitle>Anti-cancer drugs</jtitle><addtitle>Anticancer Drugs</addtitle><date>2016-11</date><risdate>2016</risdate><volume>27</volume><issue>10</issue><spage>1028</spage><epage>1032</epage><pages>1028-1032</pages><issn>0959-4973</issn><eissn>1473-5741</eissn><abstract>C-reactive protein (CRP) is an independent prognostic factor for renal cell carcinoma (RCC). The aim of the present study was to investigate the overall prognostic impact of CRP in patients with metastatic RCC treated with sorafenib. Between April 2008 and December 2014, 40 consecutive patients with metastatic RCC were treated with sorafenib at our institution. The patients were divided into two cohorts according to the pretreatment CRP level(i) a normal CRP cohort (≤0.30 mg/dl) and (ii) an elevated CRP cohort (>0.30 mg/dl). Kaplan–Meier overall survival analysis was carried out. The effects of selected variables on survival were assessed by multivariate regression using the Cox proportional hazards model. The normal CRP cohort included 16 patients (40.0%) and the elevated CRP cohort included 24 patients (60.0%). The normal CRP cohort showed significantly longer overall survival than the elevated CRP cohort (median, 52.0 vs. 17.0 months; P=0.0072). On multivariate analysis, normal CRP predicted longer overall survival (hazard ratio, 0.367; 95% confidence interval, 0.147−0.914; P=0.0313). Pretreatment normal CRP predicted better overall survival in patients with metastatic RCC treated with sorafenib and CRP level may be a useful biomarker for predicting overall survival of patients treated with sorafenib.</abstract><cop>England</cop><pub>Copyright Wolters Kluwer Health, Inc. All rights reserved</pub><pmid>27537400</pmid><doi>10.1097/CAD.0000000000000417</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-4973 |
| ispartof | Anti-cancer drugs, 2016-11, Vol.27 (10), p.1028-1032 |
| issn | 0959-4973 1473-5741 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1855072927 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Carcinoma, Renal Cell - blood Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - surgery Cohort Studies Female Humans Kidney Neoplasms - blood Kidney Neoplasms - drug therapy Kidney Neoplasms - surgery Male Middle Aged Niacinamide - analogs & derivatives Niacinamide - therapeutic use Phenylurea Compounds - therapeutic use Prognosis Proportional Hazards Models Protein Kinase Inhibitors - therapeutic use Retrospective Studies Survival Rate |
| title | Overall prognostic impact of C-reactive protein level in patients with metastatic renal cell carcinoma treated with sorafenib |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T21%3A26%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Overall%20prognostic%20impact%20of%20C-reactive%20protein%20level%20in%20patients%20with%20metastatic%20renal%20cell%20carcinoma%20treated%20with%20sorafenib&rft.jtitle=Anti-cancer%20drugs&rft.au=Fujita,%20Tetsuo&rft.date=2016-11&rft.volume=27&rft.issue=10&rft.spage=1028&rft.epage=1032&rft.pages=1028-1032&rft.issn=0959-4973&rft.eissn=1473-5741&rft_id=info:doi/10.1097/CAD.0000000000000417&rft_dat=%3Cproquest_cross%3E1823034162%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1823034162&rft_id=info:pmid/27537400&rfr_iscdi=true |